DGAP-Ad hoc: Geratherm Medical AG

DGAP-Adhoc: Geratherm Medical AG: Geratherm Medical announces preliminary financial figures 2015: Our best business year to date

Geratherm Medical AG / Key word(s): Preliminary Results

17.03.2016 15:49

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Ad-hoc-Meldung nach § 15 WpHG übermittelt durch die DGAP - ein Unternehmen der Equity Story AG. Für den Inhalt der Mitteilung ist der Emittent verantwortlich.

Geratherm Medical announces preliminary financial figures 2015: Our best business year to date

- Strong growth in sales and earnings

- Sales volume EUR 21.6 million +15.4 %

- Gross profit margin 65.4 % (2014: 64.4 %)

- EBITDA EUR 3.423 million +7.9 %; EBITDA margin 15.9 % (2014: 16.9 %)

- EBIT EUR 2.534 million +4.9 %; EBIT margin 11.7 % (2014: 12.9 %)

- Financial result 794 kEUR (2014: -164 kEUR).

- Results from ordinary business activities EUR 3.328 million (+47.8 %)

- Shareholder earnings (EAT) EUR 2.701 million (+60.6 %)

- Earnings per share 55 EUR cent (2014: 34 EUR cents)

- Proposed dividend 50 EUR cent per share (2014: 25 EUR cents)

Geschwenda,17. March 2016 - Geratherm Medical was able to show for the 2015 fiscal year its best business performance so far with consolidated profits amounting to EUR 2.701 million. All product segments made a positive earnings contribution. The subsidiary Geratherm do Brasil had an unfavourable impact of -987 kEUR, where currency losses accounted for 488 kEUR, on the group's operating result for the period. The losses have already been compensated in the results reported above. We are anticipating that turnover and profit growth will continue for 2016.

The in-depth annual report will be published on 26 April 2016.

Short company profile: Geratherm Medical is an internationally operating medical products enterprise with the business areas Healthcare Diagnostic, Medical Warming Systems, Cardio/Stroke and Respiratory. Our company's roots are in temperature measurement in the medical sphere. In this business area we offer a broad spectrum of products, most of which have unique selling points. We supply our customers/patients with high-quality products ranging from thermometers to complex warming systems for use in the operating theatre and by emergency rescue services and MRI Diagnostic Incubator Systems for premature babies and newborns. In the Cardio business area we concentrate on the development of products for the detection of atrial fibrillation as a measure to prevent strokes. The Respiratory segment develops and markets products for the assessment of pulmonary function. In all mainly business areas, Geratherm has patent-protected basic technologies at its disposal. We regard ourselves as a research-based medical products company with a clear focus on medical diagnostic devices that generate vital data. Geratherm shares have been listed in the Prime Standard segment of the Frankfurt Stock Exchange since the year 2000. Geratherm Medical continues to be represented in the German Entrepreneurial Index and in the German Healthcare Index.

Geratherm Medical AG, Investor Relations Fahrenheitstraße 1, 98716 Geschwenda Tel. +49 (0)36205/98 111 Fax: +49 (0)36205/98 115 www.geratherm.com

17.03.2016 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de

--------------------------------------------------------------------------- Language: English Company: Geratherm Medical AG Fahrenheitstraße 1 98716 Geschwenda Germany Phone: +49 (0)36205 98-0 Fax: +49 (0)36205 98-1 15 E-mail: info@geratherm.com Internet: www.geratherm.com ISIN: DE0005495626 WKN: 549562 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------